At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.
View Top Employees from Avid RadiopharmaceuticalsWebsite | http://www.avidrp.com |
Revenue | $37.8 million |
Employees | 118 (106 on RocketReach) |
Founded | 2005 |
Address | 3711 Market Street Suite 700, Philadelphia, Pennsylvania 19104, US |
Phone | (215) 298-0700 |
Fax | (413) 826-0416 |
Technologies |
JavaScript,
Microsoft Outlook,
GoDaddy DNS
+13 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Hospitals & Clinics, Discovery Tools (Healthcare), Radiopharmaceuticals, Healthcare, PET imaging, Dementia, Diabetes |
Web Rank | 12 Million |
Keywords | Early Detection, Diagnostic Imaging, Molecular Imaging |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325412 Companies |
Looking for a particular Avid Radiopharmaceuticals employee's phone or email?
The Avid Radiopharmaceuticals annual revenue was $37.8 million in 2024.
106 people are employed at Avid Radiopharmaceuticals.
Avid Radiopharmaceuticals is based in Philadelphia, Pennsylvania.
The NAICS codes for Avid Radiopharmaceuticals are [325, 3254, 32541, 32, 325412].
The SIC codes for Avid Radiopharmaceuticals are [28, 283].